急性不補償性心不全の患者におけるチアジドとループ利尿剤の併用治療の有効性と安全性: 遡及的なコホート研究
Chia-Chen Hsu1,2, Hsien-Chih Chiu1,2, Ju-Chieh Wung1,2,3
1Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.
British journal of clinical pharmacology
|August 27, 2025
まとめ
急性無補償性心不全 (ADHF) に対して,ループ利尿剤とヒドロクロロチアジド (HCTZ) を併用すると,体重減少は改善されたが,急性腎臓損傷と腎機能の悪化のリスクは増加した.
科学分野:
- 心臓病科
- 腎臓科
- 薬理学について
背景:
- 急性無補償性心不全 (ADHF) は,効果的な流体管理を必要とする複雑な状態です.
- 利尿薬療法はADHFにおける液体の過剰負荷管理の基石である.
研究 の 目的:
- ADHF患者における循環性尿薬とヒドロクロチアジド (HCTZ) の併用に関連する要因を調査する.
- この併用治療の効果と安全性を,ループ利尿剤のみと比較して評価する.
主な方法:
- 2016年1月から2023年3月までの間,静脈回路の利尿薬を投与されたADHFのために入院した成人の遡及的研究.
- 患者は2つのグループに分けられ,ループ利尿剤単独療法とHCTZとの併用療法である.
- 体重変化,急性腎臓損傷 (AKI),腎機能を含む併用療法に関連する要因と臨床結果の分析.
主要な成果:
- 併用治療は,入院前のチアジド使用,高回路利尿薬用量,低 eGFR,高NT-proBNP,および低アルバミンとの関連がありました.
- 併用療法を受けた患者はより大きな体重減少 (-1. 2kg) と体重減少率 (-1. 8%) を経験した.
- 併用治療は,AKIの高リスク (aOR: 2. 7) と退院後の腎機能の悪化 (aOR: 2. 4) と関連していた.
結論:
- ループ利尿剤とHCTZを併用した治療は,ADHF患者の体重減少を助長する.
- AKIや腎機能の悪化を含む腎機能障害のリスクが増加する可能性があります.
関連する概念動画
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
870
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
870
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
761
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
761